Flobufen (VUFB 16066) is a non-steroidal anti-inflammatory agent and cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) inhibitor agent. Flobufen inhibits alloantigen-driven cellular immune responses and stimulates phagocytosis of peritoneal cells. Flobufen can improve immunopathological disorders and has an inhibitory effect on rheumatoid arthritis.
References:
[1]. Kvasnicková E, et al. Metabolic pathways of flobufen-a new antirheumatic and antiarthritic drug. Interspecies comparison. Exp Toxicol Pathol. 1999 Jul;51(4-5):352-6.
[2]. Panajotova V, et al. Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-metl-4-oxobutanoic acid. Arzneimittelforschung.
[3]. Drsata J, et al. Inhibice dekarboxylázy aromatických aminokyselin protizánĕtlivými látkami flobufenem a kyselinou 2',4'-difluorbifenyl-4-yloctovou [Inhibition of aromatic amino acid decarboxylases by the anti-inflammatory agent flobufen and 2',4'-difluorbiphenyl-4-acetic acid]. Cesk Farm. 1989 Nov;38(9):407-10.